Results 71 to 80 of about 58,715 (237)
Chemotherapy treatment of multiple myeloma patients increases circulating levels of endothelial microvesicles [PDF]
, 2016 Correspondenc
Adesanya, M. Adeola +5 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler +4 more
wiley +1 more source
Signal Transduction and Targeted Therapy, 2021 Thalidomide induces γ-globin expression in erythroid progenitor cells, but its efficacy on patients with transfusion-dependent β-thalassemia (TDT) remains unclear.
Jiang-Ming Chen +30 more
doaj +1 more source
Research progress on the role of inflammatory mediators in the pathogenesis of epilepsy
Ibrain, Volume 11, Issue 1, Page 44-58, Spring 2025.In the central nervous system, activated immune cells lead to the overproduction of inflammatory mediators through the corresponding signal pathway. Under the stimulation of inflammatory factors, neuroinflammation ultimately occurs. Overexpression of inflammatory mediators and activated immunocytes plays an important role in the emergence and ...
Yue Yu, Fei‐Ji Sun
wiley +1 more source
Novel thalidomide analogues, “me too†drugs and the Brazilian law
Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia, 2013 In Brazil, thalidomide has been used virtually without interruption since it was launched as a new and revolutionary sedative drug in 1956. After 1965, when its efficacy to treat erythema nodosum leprosum (ENL) was discovered, it was regarded as an ...
Francisco José Roma Paumgartten
doaj +2 more sources
Thalidomide in treatment of connective diseases and vasculities
Reumatismo, 2011 Thalidomide is an immunomodulatory, anti-inflammatory and anti-angiogenic drug. Thalidomide exerts its effects by decreasing circulating CD4 positive T-cells and stimulating CD8 positive T-cells, by increasing the number of Natural Killer cells and T ...
D. Ribatti, F.P. Cantatore, N. Maruotti
doaj +1 more source
International Journal of Cancer, EarlyView.What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins +3 more
wiley +1 more source
Structural dynamics of the cereblon ligand binding domain.
PLoS ONE, 2015 Cereblon, a primary target of thalidomide and its derivatives, has been characterized structurally from both bacteria and animals. Especially well studied is the thalidomide binding domain, CULT, which shows an invariable structure across different ...
Marcus D Hartmann +4 more
doaj +1 more source
, 1999 The second in a series re-evaluating hazards identified in the 1950s and ...
Jacobson, Kevin, Mazur, Allan
core +1 more source
Surgical Reconstruction in Pyoderma Gangrenosum, a Retrospective Study of Five Patients
JEADV Clinical Practice, EarlyView.ABSTRACT Pyoderma Gangrenosum (PG) is a neutrophilic dermatosis characterized by chronic painful ulcerations most commonly on the lower extremities. Current treatment options for PG are largely nonsurgical and include the use of systemic and topical immunomodulators and wound care.
Max E. Oscherwitz +8 more
wiley +1 more source